RECORD // Company

Zenas BioPharma, Inc.

Formerly: Zenas BioPharma (Cayman) Ltd

Built 2026-11-21T18:23:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (4)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • ZENAS BIOPHARMA (USA) LLC · Ct business · exact name match to 'Zenas BioPharma, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • Zenas BioPharma (USA), LLC · Ctgov · exact name match to 'Zenas BioPharma, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • Zenas BioPharma (USA) LLC · East licences · exact name match to 'Zenas BioPharma, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ZENAS BIOPHARMA (USA) LLC · Ny corps · exact name match to 'Zenas BioPharma, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001104659-26-123040

ItemValuePeriodFormFiledAccessionReport
Revenue$10,000,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1230402026-11-21 18:23 UTCReport an error
Net income (loss)$-108,923,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1230402026-11-21 18:23 UTCReport an error
Interest expense$2,058,0003 months ended 2026-09-3010-Q2026-11-050001104659-26-1230402026-11-21 18:23 UTCReport an error
Cash and cash equivalents$177,778,000at 2026-09-3010-Q2026-11-050001104659-26-1230402026-11-21 18:23 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001953926
Ticker
ZBIO
CUSIP
98937L105
Record ID
sx:sec:0001953926

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

35 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
Business address852 WINTER STREET, SUITE 250, WALTHAM, MA, 024512026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 18:23 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$10,000,0002025-12-3110-K, XBRL Revenues2026-11-21 18:23 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-377,737,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 18:23 UTCReport an error
Total assets (at 2025-12-31)$383,640,0002025-12-3110-K, XBRL Assets2026-11-21 18:23 UTCReport an error
Stockholders' equity (at 2025-12-31)$242,144,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 18:23 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$110,641,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 18:23 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-172,333,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 18:23 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$18,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 18:23 UTCReport an error
Long-term debt (at 2025-12-31)$78,636,0002025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-21 18:23 UTCReport an error
Operating lease liabilities (at 2025-12-31)$1,326,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-21 18:23 UTCReport an error
Form D total offering amount (D filed 2024-05-14)$200,145,7322024-05-14D2026-11-21 18:23 UTCReport an error
Form D total amount sold (D filed 2024-05-14)$200,145,7322024-05-14D2026-11-21 18:23 UTCReport an error
Form D industry groupBiotechnology2024-05-14D2026-11-21 18:23 UTCReport an error
Form D revenue rangeDecline to Disclose2024-05-14D2026-11-21 18:23 UTCReport an error
Form D date of first sale2024-05-032024-05-14D2026-11-21 18:23 UTCReport an error
8-K Item 8.01 (filed 2026-11-06)Other Events As previously disclosed, on October 8, 2025, Zenas BioPharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), through the Sales Agent. The Company previously filed a registration statement on Form S-3ASR (File No. 333-290777) (the “Registration Statement”) with the Securities and Exchange Commission on October 8, 2025, which included a sales agreement prospectus supplement relating to the offer…2026-11-06SEC EDGAR 8-K 0001104659-26-123885 (text as filed, excerpt)2026-11-21 18:23 UTCReport an error
8-K Item 2.02 (filed 2026-11-05)Results of Operations and Financial Condition. On November 5, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K and the exhibit furnished under Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the…2026-11-05SEC EDGAR 8-K 0001104659-26-123035 (text as filed, excerpt)2026-11-21 18:23 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-13)On October 12, 2026, the Company issued a press release announcing new data from its Phase 3 trial of obexelimab in immunoglobulin G4-related disease, including, but not limited to, open label extension data. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K and the exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they…2026-10-13SEC EDGAR 8-K 0001104659-26-115151 (text as filed, excerpt)2026-11-21 18:23 UTCReport an error
8-K Item 2.02 (filed 2026-08-13)Results of Operations and Financial Condition. On August 13, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K and the exhibit furnished under Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the…2026-08-13SEC EDGAR 8-K 0001104659-26-095437 (text as filed, excerpt)2026-11-21 18:23 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain Officers; Election (filed 2026-08-13)of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Christy J. Oliger Upon the recommendation of the Nominating and Corporate Governance Committee of the Company’s Board of Directors (the “Board”), on August 12, 2026, the Board appointed Christy J. Oliger to serve on the Board as a Class II director to hold office until the Company’s annual meeting of stockholders in 2029 and until her successor is duly elected and qualified, or her earlier death, resignation or removal, with such appointment to be effective as of September 1, 2026 (the “Appointment Date”). The Board determined that Ms. Oliger is independent under the applicable…2026-08-13SEC EDGAR 8-K 0001104659-26-095437 (text as filed, excerpt)2026-11-21 18:23 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$241,280,0712026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #2 (13F as filed): SR One Capital Management, LP$127,860,7352026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #3 (13F as filed): NEA Management Company, LLC$102,109,2982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #4 (13F as filed): ENAVATE SCIENCES GP, LLC$99,468,2552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #5 (13F as filed): FEDERATED HERMES, INC.$79,104,5112026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #6 (13F as filed): BlackRock, Inc.$68,176,3892026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #7 (13F as filed): Capital International Investors$63,523,9072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #8 (13F as filed): Polar Capital Holdings Plc$61,236,1532026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #9 (13F as filed): Royalty Pharma Sub-Manager, LLC$60,611,2472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error
Largest institutional holder #10 (13F as filed): Fairmount Funds Management LLC$59,872,0552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-21 18:23 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.